- Conditions
- Breast Cancer, Ductal Carcinoma in Situ
- Interventions
- Not listed
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 307
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Biospecimen Collection, Bone Mineral Density Test, Questionnaire Administration, WBF-038
- Procedure · Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor, Selective estrogen receptor modulator (SERM)
- Biological · Drug
- Lead sponsor
- Finn, Olivera, PhD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Tubular Ductal Breast Carcinoma
- Interventions
- external beam radiation therapy, questionnaire administration, therapeutic conventional surgery
- Radiation · Other · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Orange, Ohio • Westlake, Ohio
- Conditions
- Early Stage Breast Cancer (Stage 0-III)
- Interventions
- Exercise Regimen
- Other
- Lead sponsor
- Nevada Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
- Interventions
- Follow-Up, Physical Examination, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Neoplasms
- Interventions
- Permanent Breast Seed Implant (PBSI)
- Radiation
- Lead sponsor
- Concure Oncology-Breast Microseed Inc.
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 3
- States / cities
- Pittsburgh, Pennsylvania • Fredericksburg, Virginia • Seattle, Washington
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 90 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- MarginProbe, Lumpectomy
- Device · Procedure
- Lead sponsor
- Dune Medical Devices
- Industry
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 18
- States / cities
- Costa Mesa, California • Los Angeles, California • Newport Beach, California + 8 more
- Conditions
- Cancer Survivor, Early-Stage Breast Carcinoma, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- Educational Intervention, Laboratory Biomarker Analysis, Meditation Therapy, Questionnaire Administration
- Other · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Up to 49 Years · Female only
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Atypical Ductal Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
- Interventions
- metformin hydrochloride, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 25 Years to 55 Years · Female only
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 27
- States / cities
- Duarte, California • Los Angeles, California • South Pasadena, California + 18 more
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
- Interventions
- Agent Affecting Integumentary System, Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Cancer, Hot Flashes, Sleep Disorders
- Interventions
- venlafaxine, zolpidem tartrate, management of therapy complications
- Drug · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer
- Interventions
- Complete a health questionnaire, Provide a saliva sample for genetic testing, Screening advice based on a comprehensive risk assessment, Screening advice based on a basic risk assessment
- Other · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 30 Years to 74 Years · Female only
- Enrollment
- 100,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2029
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Irvine, California • Los Angeles, California + 8 more
- Conditions
- Breast Cancer
- Interventions
- pegylated liposomal doxorubicin hydrochloride, DNA methylation analysis, TdT-mediated dUTP nick end labeling assay, fluorescence in situ hybridization, loss of heterozygosity analysis, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, breast duct lavage, neoadjuvant therapy, therapeutic conventional surgery
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Dr. Susan Love Research Foundation
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 2
- States / cities
- Eureka, California • Santa Monica, California
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Questionnaire Administration
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer, Depression, Fatigue, Pain
- Interventions
- Yoga Therapy
- Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- Magtrace
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Behavioral, Psychological or Informational Intervention, Best Practice, Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma, Invasive Lobular Breast Carcinoma With Predominant in Situ Component, Liver Metastases, Lobular Breast Carcinoma in Situ, Lung Metastases, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Tubular Ductal Breast Carcinoma, Tumors Metastatic to Brain
- Interventions
- hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
- Radiation · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2024
- U.S. locations
- 1
- States / cities
- North Chicago, Illinois
- Conditions
- Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
- Interventions
- Cancer Educational Materials, Decision Aid, Interview, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 412 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 96
- States / cities
- Antioch, California • Costa Mesa, California • Duarte, California + 67 more
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Mammography, Questionnaire Administration, Tamoxifen
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Chicago, Illinois • Kansas City, Kansas + 6 more
- Conditions
- Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
- Interventions
- ADV/HSV-tk, Valacyclovir, SBRT, Pembrolizumab
- Biological · Drug · Radiation
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
- Interventions
- Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration
- Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 928 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 15
- States / cities
- Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 11 more